Ramaswamy Govindan, MD, of Washington University School of Medicine, discusses sex differences in lung cancer, including variations in treatment response, and the state of research in the field (Session ED20).
Antoni Ribas, MD, PhD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, summarizes the opening plenary session that addressed epigenetics and early detection, how the aging microenvironment governs response to therapy, AI-driven precision medicine, reprogramming human T cells, and opportunities for the future.
Elizabeth H. Stover, MD, PhD, of Dana-Farber Cancer Institute, discusses an analysis of genomic alterations in patients with relapsed ovarian cancer who were treated with nivolumab plus bevacizumab in a phase II clinical trial. The study was conducted to identify potential biomarkers of response (Abstract 1048).
Robert A. Winn, MD, of Virginia Commonwealth University and the Massey Cancer Center, discusses the COVID-19 pandemic and how it is exacerbating disparities in cancer care among racial and ethnic minorities and the medically underserved who are disproportionately affected by the coronavirus (Session VSS06).
Ralph R. Weichselbaum, MD, of the University of Chicago Cancer Research Center, explores the question of whether radiotherapy is the principal curative treatment with immunotherapy or activates immunotherapy. He also discussed how to improve the interaction of these treatments, perhaps with vaccination, transfer of genetically engineered T cells, or checkpoint inhibitors (Session ED37).
Alfonso Bencomo Álvarez, PhD, of Texas Tech University Health Sciences Center, discusses his retrospective study of the incidence and survival for patients with hematologic malignancies residing at the United States/Mexico border. The analysis showed that 10-year survival rates for Hispanic patients with ALL, AML, and CML were significantly lower for those who lived in El Paso than for those who lived elsewhere in Texas (Abstract 4343).
